Novartis Prexige NDA Re-Submission Expected In 2006; TARGET Data “Clean”
Novartis expects to re-submit an NDA for the COX-2 inhibitor Prexige by early 2006 following the completion of several studies requested by FDA in a "not approvable" letter
Novartis expects to re-submit an NDA for the COX-2 inhibitor Prexige by early 2006 following the completion of several studies requested by FDA in a "not approvable" letter